Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.None of the roughly 2,000 women in the trial who received Gilead's shot lenacapavir had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer the treatment to everyone in the study. Other participants had received standard daily pills.The results bring Gilead one step closer to introducing a ...

Gilead Sciences (GILD) closed at $63.56 in the latest trading session, marking a -1.21% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.23%. Elsewhere, the Dow saw a downswing of 0.17%, while the tech-heavy Nasdaq appreciated by 0.34%.The HIV and hepatitis C drugmaker's stock has dropped by 3.98% in the past month, falling short of the Medical sector's gain of 2.69% and the S&P 500's gain of 3.96%.Analysts and investors alike will be keeping a close eye on the perf ...

Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead’s June 4th press release reported in the San Francisco Chronicle SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- In a recent press release (reported in The San Francisco Chronicle on June 4th), California pharma giant Gilead touts a $40 million settlement to resolve the lawsuits of approximately 2,625 plaintiffs. At the same time, it brushes off its culpability for del ...

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining. We're really pleased to have the Gilead team who has joined us virtually, unfortunately, due to the weather. It was hard to make it here in person. With us, we have Dan O'Day, Chairman and ...

These stocks offer great dividends and more.Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.Three Motley Fool contributors have found stocks with mouthwatering dividends that you can buy right now. Here's why they picked Gilead Sciences (GILD 1.33%), Organon (OGN 0.39%), and Pfizer (PFE -0.76%).A safe, reliable dividend payerProsper Junior Bakiny (Gilead Sciences): When looking for so ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about. Question-and-Answer Session Q - Michael Yee Maybe just opening up for Gilead, I'd love to just have y ...

Gilead Sciences, Inc. (GILD) and partner Arcus Biosciences, Inc. (RCUS) announce new data from Cohort B of the ARC-9 study.ARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b adenosine receptor antagonist, plus anti-PD-1 antibody zimberelimab (Z), FOLFOX and bevacizumab (“EZFB”), in three cohorts of patients suffering from metastatic colorectal cancer (mCRC).Cohort B of ARC-9 randomized 112 patients with comparable baseline characteristics between two arms: EZ ...

ffikretow/iStock via Getty Images My last article about Gilead Sciences, Inc. (NASDAQ:GILD) was published in August 2023 and once again the stock declined while the overall market outperformed. Back then, the stock was trading for $77, and Gilead Sciences declined 12% while the S&P 500 (SPY) increased 20% in the same timeframe. But the story that Gilead Sciences underperformed the S&P 500 is not news at this point. Gilead Sciences underperformed the S&P 500 basically on every timeframe - 6 months, 1 year, 3 ...

Olivier Le Moal I will say this pick is based more on a hunch (honed over 37 years of trading) than any concrete news catalyst or technical trading evidence. I bought a stake in Gilead Sciences (NASDAQ:GILD) recently on the view a bear market and recession will eventually force investors to move money into defensive ideas like pharmaceuticals. This group has an excellent history of witnessing massive flight-to-safety money flows during stressful periods overall on Wall Street. Specifically, Gilead has p ...